Pacific Biosciences of California, Inc. (PACB) Gross profit 2016–2025
Pacific Biosciences of California, Inc. (PACB) annual gross profit history from SEC filings — each fiscal year as reported.
$45.8MFY2025 · since FY2016: $44.2M → $45.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $45.8M | +22.8% |
| FY2024 | $37.3M | -29.4% |
| FY2023 | $52.8M | +7.6% |
| FY2022 | $49.0M | -16.7% |
| FY2021 | $58.9M | +80.7% |
| FY2020 | $32.6M | -5.8% |
| FY2019 | $34.6M | +37.8% |
| FY2018 | $25.1M | -27.6% |
| FY2017 | $34.7M | -21.5% |
| FY2016 | $44.2M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More PACB financial trends
PACB RevenuePACB Net incomePACB Net marginPACB Gross marginPACB Operating incomePACB Operating marginPACB Operating cash flowPACB Free cash flowPACB Capital expendituresPACB Return on equityPACB Stock buybacksPACB Dividends paidPACB Total assetsPACB Total liabilitiesPACB Shareholders’ equityPACB overview →